-
2025-524181-26-00
4
relapsed/refractory multiple myeloma
-
2025-524322-18-00
5
Non-active Secondary Progressive Multiple Sclerosis (SPMS)
-
2025-524613-89-00
9
HER2 positive advanced breast cancer
-
2025-524646-94-00
11
Obstetrics – Preeclampsia
-
2025-525158-20-00
1
Stage IIB/C, Stage III, or Stage IV Melanoma
-
2025-524810-28-00
5
2026-07-02
Acute Promyelocytic Leukemia
-
2025-521709-42-00
5
2026-06-23
Allergic rhinoconjunctivitis with or without asthma due to clinically
-
2025-523586-18-00
5
2026-06-11
Non-Small Cell Lung Cancer
-
2025-524316-11-00
5
2026-06-11
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524408-30-01
5
2026-06-05
Metastatic hormone-sensitive prostate cancer
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522145-21-00
5
2026-04-13
Metastatic hormone sensitive prostate cancer
-
2024-512436-29-00
11
2026-03-27
CARDIOVASCULAR DISEASES
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2025-522553-19-00
10
2026-02-25
Symptomatic genetic and familial dilated cardiomyopathy.
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2024-520433-76-00
4
2026-01-08
Newly Diagnosed Multiple Myeloma
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-522455-26-00
9
2025-12-17
Acute Ischemic Stroke
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2025-521251-24-00
4
2025-12-01
Non-Small cell lung cancer (NSCLC)
-
2025-521040-37-00
5
2025-11-26
HER2-positive early breast cancer